Osteo-renal cross-talk and phosphate metabolism by the FGF23-klotho system

Contributions to Nephrology

Volumn 180, Issue , 2013, Pages 1-13

  Ohnishi, Mutsuko ^a   Razzaque, Mohammed S ^a  

^a HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892498831     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000346774     Document Type: Article

References (94)

1. Gaasbeek A, Meinders AE. Hypophosphatemia: an update on its etiology and treatment. Am J Med 2005; 118: 1094-1101
2. ADHR-Consortium: Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. The ADHR consortium. Nat Genet 2000; 26: 345-348
3. Tenenhouse HS. X-linked hypophosphataemia: a homologous disorder in humans and mice. Nephrol Dial Transplant 1999; 14: 333-341
4. Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer 2011; 18: R53-R77
5. Endo I, Fukumoto S, Ozono K, Namba N, Tanaka H, Inoue D, Minagawa M, Sugimoto T, Yamauchi M, Michigami T, Matsumoto T. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Bone 2008; 42: 1235-1239
6. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001; 98: 6500-6505
7. Razzaque MS. FGF23-mediated regulation of systemic phosphate homeostasis: is klotho an essential player? Am J Physiol Renal Physiol 2009; 296: F470-F476
8. Iotti S, Lodi R, Gottardi G, Zaniol P, Barbiroli B. Inorganic phosphate is transported into mitochondria in the absence of ATP biosynthesis: an in vivo 31P NMR study in the human skeletal muscle. Biochem Biophys Res Commun 1996; 225: 191-194
9. Osuka S, Razzaque MS. Can features of phosphate toxicity appear in normophosphatemia? J Bone Miner Metab 2012; 30: 10-18
10. Nagy AK, Kane DJ, Tran CM, Farley RA, Faller LD. Evidence calcium pump binds magnesium before inorganic phosphate. J Biol Chem 2005; 280: 7435-7443
11. Pedemonte CH, Beauge L. Inhibition of (Na + , K + )-ATPase by magnesium ions and inorganic phosphate and release of these ligands in the cycles of ATP hydrolysis. Biochim Biophys Acta 1983; 748: 245-253
12. Hansen O. The effect of sodium on inorganic phosphate-And p-nitrophenyl phosphate-facilitated ouabain binding to (Na + + K + )-Activated ATPase. Biochim Biophys Acta 1978; 511: 10-22
13. Reed JB, Smith SD, Forbes AB, Doxey DL. Inorganic phosphate, calcium and magnesium levels in the sera of Botswanan cattle receiving feed additives. Trop Anim Health Prod 1974; 6: 31-36
14. Razzaque MS. Osteo-renal regulation of systemic phosphate metabolism. IUBMB Life 2011; 63: 240-247
15. Berndt T, Kumar R. Novel mechanisms in the regulation of phosphorus homeostasis. Physiology (Bethesda) 2009; 24: 17-25
16. Razzaque MS. The FGF23-klotho axis: endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol 2009; 5: 611-619
17. Marks J, Debnam ES, Unwin RJ. Phosphate homeostasis and the renal-gastrointestinal axis. Am J Physiol Renal Physiol 2010; 299: F285-F296
18. Hattenhauer O, Traebert M, Murer H, Biber J. Regulation of small intestinal Na-Pi type IIb cotransporter by dietary phosphate intake. Am J Physiol Gastrointest Liver Physiol 1999; 277: G756-G762
19. Sabbagh Y, O'Brien SP, Song W, Boulanger JH, Stockmann A, Arbeeny C, Schiavi SC. Intestinal NPT2b plays a major role in phosphate absorption and homeostasis. J Am Soc Nephrol 2009; 20: 2348-2358
20. Corut A, Senyigit A, Ugur SA, Altin S, Ozcelik U, Calisir H, Yildirim Z, Gocmen A, Tolun A. Mutations in SLC34A2 cause pulmonary alveolar microlithiasis and are possibly associated with testicular microlithiasis. Am J Hum Genet 2006; 79: 650-656
21. Razzaque MS. Phosphate toxicity: new insights into an old problem. Clin Sci (Lond) 2011; 120: 91-97
22. Miyamoto K, Ito M, Tatsumi S, Kuwahata M, Segawa H. New aspect of renal phosphate reabsorption: the type IIc sodium-dependent phosphate transporter. Am J Nephrol 2007; 27: 503-515
23. Tenenhouse HS. Phosphate transport: molecular basis, regulation and pathophysiology. J Steroid Biochem Mol Biol 2007; 103: 572-577
24. Lorenz-Depiereux B, Benet-Pages A, Eckstein G, Tenenbaum-Rakover Y, Wagenstaller J, Tiosano D, Gershoni-Baruch R, Albers N, Lichtner P, Schnabel D, Hochberg Z, Strom TM. Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium-phosphate cotransporter gene SLC34A3. Am J Hum Genet 2006; 78: 193-201
25. Beck L, Karaplis AC, Amizuka N, Hewson AS, Ozawa H, Tenenhouse HS. Targeted inactivation of NPT2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities. Proc Natl Acad Sci USA 1998; 95: 5372-5377
26. Segawa H, Onitsuka A, Shiozawa K, Aranami F, Tatsumi S, Ito M, Kuwahata M, Miyamoto K. Roles of type IIc Na/Pi cotransporters in body pi homeostasis. J Am Soc Nephrol 2006; 17: 355A
27. Tenenhouse HS. Regulation of phosphorus homeostasis by the type IIa Na/phosphate cotransporter. Annu Rev Nutr 2005; 25: 197-214
28. Biber J, Custer M, Magagnin S, Hayes G, Werner A, Lotscher M, Kaissling B, Murer H. Renal Na/Pi-cotransporters. Kidney Int 1996; 49: 981-985
29. Iharada M, Miyaji T, Fujimoto T, Hiasa M, Anzai N, Omote H, Moriyama Y. Type 1 sodium-dependent phosphate transporter (SLC17A1 protein) is a Cl(-)-dependent urate exporter. J Biol Chem 2010; 285: 26107-26113
30. Suzuki A, Ammann P, Nishiwaki-Yasuda K, Sekiguchi S, Asano S, Nagao S, Kaneko R, Hirabayashi M, Oiso Y, Itoh M, Caverzasio J. Effects of transgenic Pit-1 overexpression on calcium phosphate and bone metabolism. J Bone Miner Metab 2010; 28: 139-148
31. Festing MH, Speer MY, Yang HY, Giachelli CM. Generation of mouse conditional and null alleles of the type III sodium-dependent phosphate cotransporter Pit-1. Genesis 2009; 47: 858-863
32. Caldas Y, Giral H, Sorribas V, Levi M. Nuclear receptor LXR: a new partner for sodiumdependent phosphate cotransporters. Contrib Nephrol. Basel, Karger, 2013, vol 180, pp 64-73
33. Kido S, Kaneko I, Tatsumi S, Segawa H, Miyamoto K. Vitamin D and type II sodiumdependent phosphate cotransporters. Contrib Nephrol. Basel, Karger, 2013, vol 180, pp 86-97
34. Quarles LD. Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 2008; 118: 3820-3828
35. Baum M, Schiavi S, Dwarakanath V, Quigley R. Effect of fibroblast growth factor-23 on phosphate transport in proximal tubules. Kidney Int 2005; 68: 1148-1153
36. Kanatani M, Sugimoto T, Kano J, Kanzawa M, Chihara K. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity. J Cell Physiol 2003; 196: 180-190
37. Prie D, Torres PU, Friedlander G. Phosphate handling: new genes, new molecules. Horm Res Paediatr 2011; 76(suppl 1): 71-75
38. Razzaque MS. The dualistic role of vitamin D in vascular calcifications. Kidney Int 2011; 79: 708-714
39. Razzaque MS. Does FGF23 toxicity influence the outcome of chronic kidney disease? Nephrol Dial Transplant 2009; 24: 4-7
40. Drueke TB. Klotho, FGF23, and FGF receptors in chronic kidney disease: a yin-yang situation? Kidney Int 2010; 78: 1057-1060
41. Razzaque MS, Lanske B. The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. J Endocrinol 2007; 194: 1-10
42. Bastepe M, Juppner H. Inherited hypophosphatemic disorders in children and the evolving mechanisms of phosphate regulation. Rev Endocr Metab Disord 2008; 9: 171-180
43. Benet-Pages A, Orlik P, Strom TM, Lorenz-Depiereux B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 2005; 14: 385-390
44. Goetz R, Beenken A, Ibrahimi OA, Kalinina J, Olsen SK, Eliseenkova AV, Xu C, Neubert TA, Zhang F, Linhardt RJ, Yu X, White KE, Inagaki T, Kliewer SA, Yamamoto M, Kurosu H, Ogawa Y, Kuroo M, Lanske B, Razzaque MS, Mohammadi M. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 2007; 27: 3417-3428
45. Goetz R, Nakada Y, Hu MC, Kurosu H, Wang L, Nakatani T, Shi M, Eliseenkova AV, Razzaque MS, Moe OW, Kuroo M, Mohammadi M. Isolated C-Terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-klotho complex formation. Proc Natl Acad Sci USA 2010; 107: 407-412
46. Goetz R, Ohnishi M, Kir S, Kurosu H, Wang L, Pastor J, Ma J, Gai W, Kuroo M, Razzaque MS, Mohammadi M. Conversion of a paracrine fibroblast growth factor into an endocrine fibroblast growth factor. J Biol Chem 2012; 287: 29134-29146
47. Goetz R, Ohnishi M, Ding X, Kurosu H, Wang L, Akiyoshi J, Ma J, Gai W, Sidis Y, Pitteloud N, Kuro OM, Razzaque MS, Mohammadi M. Klotho coreceptors inhibit signaling by paracrine fibroblast growth factor 8 subfamily ligands. Mol Cell Biol 2012; 32: 1944-1954
48. Kuroo M. Klotho as a regulator of fibroblast growth factor signaling and phosphate/calcium metabolism. Curr Opin Nephrol Hypertens 2006; 15: 437-441
49. Medici D, Razzaque MS, Deluca S, Rector TL, Hou B, Kang K, Goetz R, Mohammadi M, Kuro OM, Olsen BR, Lanske B. FGF-23-klotho signaling stimulates proliferation and prevents vitamin D-induced apoptosis. J Cell Biol 2008; 182: 459-465
50. Nabeshima Y. The discovery of alpha-klotho and FGF23 unveiled new insight into calcium and phosphate homeostasis. Cell Mol Life Sci 2008; 65: 3218-3230
51. Razzaque MS. The role of klotho in energy metabolism. Nat Rev Endocrinol 2012; 8: 579-587
52. Matsumura Y, Aizawa H, Shiraki-Iida T, Nagai R, Kuroo M, Nabeshima Y. Identification of the human klotho gene and its two transcripts encoding membrane and secreted klotho protein. Biochem Biophys Res Commun 1998; 242: 626-630
53. Maeda R, Imura A, Nabeshima Y. Complex regulation and diverse functions of a-klotho. Contrib Nephrol. Basel, Karger, 2013, vol 180, pp 25-46
54. Nakatani T, Ohnishi M, Razzaque MS. Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (HYP) mouse model. FASEB J 2009; 23: 3702-3711
55. Nakatani T, Sarraj B, Ohnishi M, Densmore MJ, Taguchi T, Goetz R, Mohammadi M, Lanske B, Razzaque MS. In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (FGF23)-mediated regulation of systemic phosphate homeostasis. FASEB J 2009; 23: 433-441
56. Ohnishi M, Kato S, Akiyoshi J, Atfi A, Razzaque MS. Dietary and genetic evidence for enhancing glucose metabolism and reducing obesity by inhibiting klotho functions. FASEB J 2011; 25: 2031-2039
57. Ohnishi M, Nakatani T, Lanske B, Razzaque MS. In vivo genetic evidence for suppressing vascular and soft-Tissue calcification through the reduction of serum phosphate levels, even in the presence of high serum calcium and 1, 25-dihydroxyvitamin D levels. Circ Cardiovasc Genet 2009; 2: 583-590
58. Ohnishi M, Nakatani T, Lanske B, Razzaque MS. Reversal of mineral ion homeostasis and soft-Tissue calcification of klotho knockout mice by deletion of vitamin d 1alpha-hydroxylase. Kidney Int 2009; 75: 1166-1172
59. Ohnishi M, Razzaque MS. Dietary and genetic evidence for phosphate toxicity accelerating mammalian aging. FASEB J 2010; 24: 3562-3571
60. Sitara D, Kim S, Razzaque MS, Bergwitz C, Taguchi T, Schuler C, Erben RG, Lanske B. Genetic evidence of serum phosphate-independent functions of FGF-23 on bone. PLoS Genet 2008; 4: e1000154
61. Ichikawa S, Imel EA, Kreiter ML, Yu X, Mackenzie DS, Sorenson AH, Goetz R, Mohammadi M, White KE, Econs MJ. A homozygous missense mutation in human klotho causes severe tumoral calcinosis. J Clin Invest 2007; 117: 2684-2691
62. Bai X, Miao D, Li J, Goltzman D, Karaplis AC. Transgenic mice overexpressing human fibroblast growth factor 23(r176q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 2004; 145: 5269-5279
63. Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse HS, Juppner H, Jonsson KB. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 2004; 145: 3087-3094
64. Shimada T, Urakawa I, Yamazaki Y, Hasegawa H, Hino R, Yoneya T, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 2004; 314: 409-414
65. DeLuca S, Sitara D, Kang K, Marsell R, Jonsson K, Taguchi T, Erben RG, Razzaque MS, Lanske B. Amelioration of the premature aging-like features of FGF-23 knockout mice by genetically restoring the systemic actions of FGF-23. J Pathol 2008; 216: 345-355
66. Bai X, Dinghong Q, Miao D, Goltzman D, Karaplis AC. Klotho ablation converts the biochemical and skeletal alterations in FGF23 (r176q) transgenic mice to a klotho-deficient phenotype. Am J Physiol Endocrinol Metab 2009; 296: E79-E88
67. Razzaque MS. Therapeutic potential of klotho-FGF23 fusion polypeptides: Wo2009095372. Expert Opin Ther Pat 2010
68. Razzaque MS. FGF23, klotho and vitamin D interactions: what have we learned from in vivo mouse genetics studies? Adv Exp Med Biol 2012; 728: 84-91
69. Strom TM, Francis F, Lorenz B, Boddrich A, Econs MJ, Lehrach H, Meitinger T. Pex gene deletions in Gy and Hyp mice provide mouse models for X-linked hypophosphatemia. Hum Mol Genet 1997; 6: 165-171
70. Econs MJ, Friedman NE, Rowe PS, Speer MC, Francis F, Strom TM, Oudet C, Smith JA, Ninomiya JT, Lee BE, Bergen H. A PHEX gene mutation is responsible for adult-onset vitamin D-resistant hypophosphatemic osteomalacia: evidence that the disorder is not a distinct entity from X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 1998; 83: 3459-3462
71. Titan SM, Zatz R, Graciolli FG, dos Reis LM, Barros RT, Jorgetti V, Moyses RM. FGF-23 as a predictor of renal outcome in diabetic nephropathy. Clin J Am Soc Nephrol 2011; 6: 241-247
72. Slatopolsky E. The intact nephron hypothesis: the concept and its implications for phosphate management in CKD-related mineral and bone disorder. Kidney Int Suppl 2011; 79(S121): S3-S8
73. Martin KJ, Gonzalez EA. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat? Clin J Am Soc Nephrol 2011; 6: 440-446
74. Hruska KA, Mathew S. The roles of the skeleton and phosphorus in the CKD mineral bone disorder. Adv Chron Kid Dis 2011; 18: 98-104
75. Fukagawa M, Kazama JJ. With or without the kidney: the role of FGF23 in CKD. Nephrol Dial Transplant 2005; 20: 1295-1298
76. Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A, Miura M, Miyauchi A, Kobayashi K, Miki T, Shoji T, Ishimura E, Nishizawa Y. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 2004; 65: 1943-1946
77. Nishi H, Nii-Kono T, Nakanishi S, Yamazaki Y, Yamashita T, Fukumoto S, Ikeda K, Fujimori A, Fukagawa M. Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin Pract 2005; 101: c94-c99
78. Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, Quarles LD. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin d. J Am Soc Nephrol 2006; 17: 1305-1315
79. Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya T, Gejyo F, Fukagawa M. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 2004; 44: 250-256
80. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Juppner H, Wolf M. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16: 2205-2215
81. Li YC. Vitamin D in chronic kidney disease. Contrib Nephrol. Basel, Karger, 2013, vol 180, pp 98-109
82. Nakanishi S, Fukagawa M. Functional disorder of the parathyroid gland and vascular calcification in hemodialysis patients. Clin Calcium 2005; 15: 119-123
83. Koizumi M, Komaba H, Fukagawa M. Parathyroid function in chronic kidney disease: role of FGF23-klotho axis. Contrib Nephrol. Basel, Karger, 2013, vol 180, pp 110-123
84. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, Konig P, Kraatz G, Mann JF, Muller GA, Kohler H, Riegler P. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) study. J Am Soc Nephrol 2007; 18: 2600-2608
85. Hsu HJ, Wu MS. Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. Am J Med Sci 2009; 337: 116-122
86. Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119: 2545-2552
87. Takeshita K, Fujimori T, Kurotaki Y, Honjo H, Tsujikawa H, Yasui K, Lee JK, Kamiya K, Kitaichi K, Yamamoto K, Ito M, Kondo T, Iino S, Inden Y, Hirai M, Murohara T, Kodama I, Nabeshima Y. Sinoatrial node dysfunction and early unexpected death of mice with a defect of klotho gene expression. Circulation 2004; 109: 1776-1782
88. Hu MC, Kuroo M, Moe OW. Klotho and chronic kidney disease. Contrib Nephrol. Contrib Nephrol. Basel, Karger, 2013, vol 180, pp 47-63
89. Shutto Y, Shimada M, Kitajima M, Yamabe H, Razzaque MS. Lack of awareness among future medical professionals about the risk of consuming hidden phosphate-containing processed food and drinks. PLoS One 2011; 6: e29105
90. Raggi P, Bellasi A. Clinical assessment of vascular calcification. Adv Chronic Kidney Dis 2007; 14: 37-43
91. Razzaque MS. Phosphate toxicity and vascular mineralization. Contrib Nephrol. Basel, Karger, 2013, vol 180, pp 74-85
92. Michigami T. Extracellular phosphate as a signaling molecule. Contrib Nephrol. Basel, Karger, 2013, vol 180, pp 14-24
93. Uchihashi K, Nakatani T, Goetz T, Mohammadi M, He X, Razzaque MS. FGF23-induced hypophosphatemia persists in HYP mice deficient in the WNT co-receptor LRP6. Contrib Nephrol. Basel, Karger, 2013, vol 180, pp 124-137
94. Hartman M-L, Groppo F, Ohnishi M, Goodson JM, Hatice H, Tavares M, Yaskell T, Floros C, Behbehani K, Razzaque MS. Can salivary phosphate levels be an early biomarker to monitor the evolvement of obesity? Contrib Nephrol. Basel, Karger, 2013, vol 180, pp 138-148